UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant decline in its stock price due to disappointing results from a clinical trial for its lead drug candidate, ersodetug [4][5]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker symbol RZLT [4]. - The company is focused on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [5]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, leading to a sharp decline in the company's stock on December 11, 2025 [5]. - The highest dose of ersodetug showed reductions in hypoglycemia events, but these results were not statistically significant compared to the placebo [5]. Group 3: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to discuss their legal rights [1]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].